GLP-1R agonists for the treatment of obesity: a patent review (2015-present)

C Liu, Y Zou, H Qian - Expert Opinion on Therapeutic Patents, 2020 - Taylor & Francis
ABSTRACT Introduction Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which
is secreted by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit …
被引用次数：22 相关文章

GLP-1R agonists for the treatment of obesity: a patent review (2015-present).

C Liu, Y Zou, H Qian - Expert Opinion on Therapeutic Patents, 2020 - europepmc.org
Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which is secreted by
enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit glucoregulation …

GLP-1R agonists for the treatment of obesity: a patent review (2015-present).

C Liu, Y Zou, H Qian - 2020 - cabidigitallibrary.org
Abstract Introduction: Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which is
secreted by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit …

GLP-1R agonists for the treatment of obesity: a patent review (2015-present)

C Liu, Y Zou, H Qian - Expert opinion on therapeutic …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which is secreted
by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit …
[PDF] researchgate.net

[PDF][PDF] GLP-1R agonists for the treatment of obesity: a patent review (2015-present)

C Liu, Y Zou, H Qian - 2020 - researchgate.net
ABSTRACT Introduction: Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which
is secreted by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit …
[PDF] researchgate.net

[PDF][PDF] GLP-1R agonists for the treatment of obesity: a patent review (2015-present)

C Liu, Y Zou, H Qian - 2020 - researchgate.net
ABSTRACT Introduction: Glucagon-like peptide-1 (GLP-1) is an endogenous peptide which
is secreted by enteroendocrine L cells, GLP-1 receptor agonists (GLP-1 RAs) can exhibit …